JAKARTA - The figure of Indra Rudiansyah has been widely discussed after being identified as a member of the research group that produced the AztraZeneca COVID-19 vaccine.
In a talk session with Erick Thohir, in 2014, he started working with PT Bio Farma (Persero). After that he stated that he wanted to continue his education to S3.
Indra applied for a scholarship through the Education Fund Management Institute (LPDP) and chose Oxford and Johns Hopkins. But eventually he was accepted at Oxford majoring in Clinical Medicine.
"Finally I went to Oxford with the topic of malaria vaccine research but using viral vector technology as well," he added.
Indra also followed a trial or probation period after being there for a year. Unfortunately, the COVID-19 pandemic came.
"At that time, if I'm not mistaken, the emerging pathogen disease group didn't have too many people, but because the pandemic came, there weren't many people to be able to work with COVID," Indria explained.
Indra also joined the emerging pathogen diseases group and participated in research on the COVID-19 vaccine.
Launching his Linkedin page, Indra graduated from ITB's Bachelor of Microbiology in 2013. Then he continued his master's degree in Biotechnology ITB with the Fast Track Program and graduated in 2014.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
